

National Stem Cell Holding, Inc. to present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting.

Tuesday February 26, 2007 9:15 am ET

MOUNTAINSIDE, N.J., Feb. 27, 2007 /PRNewswire-First Call/ -- National Stem Cell Holding, Inc. (OTC: [NHGI](#) - [News](#)) today announced that its President Michael Cohen will present a Keynote Address, "A New Collaboration Model for Government Agencies, Academic Institutions and Development Stage Biotech Companies", at the Inaugural meeting of the The Stem Cell Partnering Series: Fostering Business Collaborations & Careers in Stem Cell Science, February 28-29, 2008, to be held at the University of California San Diego.

National Stem Cell President Michael Cohen, stated: " I am pleased to participate in this event which has focused much needed attention to two critically important issues facing the stem cell / Regenerative Medicine industry: the need for increasing and improving strategic collaborations among the key stakeholders namely, development stage biotech companies, academic Institutions and government agencies, together with the attendant need to develop and recruit trained scientific personnel to meet both current and future industrial demands. Failure to address these issues rapidly and effectively within the U.S. risks the significant loss of intellectual property research and development and value to industrial sectors abroad."

The Stem Cell Partnering Series is a not-for-profit organization that actively supports the development and sustainability of the stem cell industry by fostering business collaborations and career development.

For more information on National Stem Cell Holding, Inc. please contact us at the company website: www.nationalstemcell.com or www.pinksheets.com .

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-faceted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

187 Mill Lane

Mountainside, NJ 07052

Phone: (212)792-6188

ir@nationalstemcell.com

Source: National Stem Cell Holding, Inc